BFC
IBB icon

Blue Fin Capital’s iShares Biotechnology ETF IBB Stock Holding History

Blue Fin Capital’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
10,021
+32
+0.3% +$5.5K 0.28% 59
2026
Q1 		$1.69M Buy
9,989
+95
+1% +$16.2K 0.28% 61
2025
Q4 		$1.67M Hold
9,894
– – 0.26% 58
2025
Q3 		$1.43M Sell
9,894
-162
-2% -$22.1K 0.22% 64
2025
Q2 		$1.27M Sell
10,056
-104
-1% -$12.8K 0.22% 68
2025
Q1 		$1.3M Sell
10,160
-159
-2% -$21.6K 0.25% 65
2024
Q4 		$1.36M Sell
10,319
-160
-2% -$22.5K 0.25% 64
2024
Q3 		$1.53M Sell
10,479
-37
-0.4% -$5.35K 0.29% 59
2024
Q2 		$1.44M Buy
10,516
+74
+0.7% +$9.88K 0.29% 60
2024
Q1 		$1.43M Sell
10,442
-301
-3% -$41.1K 0.32% 56
2023
Q4 		$1.46M Sell
10,743
-544
-5% -$66.4K 0.37% 54
2023
Q3 		$1.38M Sell
11,287
-554
-5% -$70.5K 0.4% 57
2023
Q2 		$1.5M Buy
11,841
+260
+2% +$33.8K 0.43% 53
2023
Q1 		$1.51M Buy
11,581
+288
+3% +$37.7K 0.49% 47
2022
Q4 		$1.48M Sell
11,293
-275
-2% -$35.5K 0.54% 48
2022
Q3 		$1.35M Sell
11,568
-492
-4% -$61.1K 0.51% 51
2022
Q2 		$1.42M Buy
12,060
+589
+5% +$69.9K 0.5% 52
2022
Q1 		$1.49M Sell
11,471
-4,566
-28% -$595K 0.43% 56
2021
Q4 		$2.45M Buy
16,037
+3,721
+30% +$576K 0.68% 38
2021
Q3 		$1.99M Buy
12,316
+1,504
+14% +$253K 0.61% 42
2021
Q2 		$1.77M Buy
10,812
+112
+1% +$17.3K 0.55% 46
2021
Q1 		$1.61M Buy
10,700
+720
+7% +$114K 0.55% 50
2020
Q4 		$1.51M Buy
9,980
+1,030
+12% +$147K 0.54% 50
2020
Q3 		$1.21M Sell
8,950
-580
-6% -$78.7K 0.49% 52
2020
Q2 		$1.3M Buy
9,530
+3,222
+51% +$411K 0.58% 47
2020
Q1 		$679K Buy
6,308
+154
+3% +$17.7K 0.37% 70
2019
Q4 		$737K Buy
6,154
+806
+15% +$89.9K 0.35% 78
2019
Q3 		$532K Sell
5,348
-400
-7% -$41.9K 0.28% 85
2019
Q2 		$627K Buy
5,748
+351
+7% +$37.3K 0.32% 80
2019
Q1 		$603K Buy
5,397
+1,967
+57% +$216K 0.32% 81
2018
Q4 		$330K Sell
3,430
-1,566
-31% -$166K 0.2% 104
2018
Q3 		$609K Buy
+4,996
New +$588K 0.3% 77

Other funds holding IBB

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Blue Fin Capital's IBB Position: Q2 2026 in Review

Blue Fin Capital increased its iShares Biotechnology ETF (IBB) stake by 0.32% in Q2 2026, buying an estimated $5.5K and bringing the position to 10,021 shares worth $1.91M. The position accounts for 0.28% of the portfolio, ranked #59.

Blue Fin Capital first reported a position in IBB in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.45M in Q4 2021. 486 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Blue Fin Capital held 10,021 shares of iShares Biotechnology ETF worth $1.91M as of Q2 2026.
  • Blue Fin Capital bought 32 iShares Biotechnology ETF shares in Q2 2026, an estimated $5.5K.
  • iShares Biotechnology ETF made up 0.28% of Blue Fin Capital's portfolio in Q2 2026, its #59 holding.
  • Blue Fin Capital first reported a position in iShares Biotechnology ETF in Q3 2018 and has held it in 32 quarters since.
  • Blue Fin Capital's iShares Biotechnology ETF position peaked at $2.45M in Q4 2021.
  • 486 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Blue Fin Capital's 13F filing for Q2 2026, filed 4 Aug 2026.